IM Cannabis Corp. (IMCC) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects mixed signals: improved EBITDA and revenue growth in Germany, but significant net loss and inventory challenges. Regulatory changes in Germany and competitive pressures add uncertainty. The Q&A highlighted management's unclear responses, especially regarding margins. Despite some positive financial trends, the lack of a share repurchase program and cash position concerns suggest a cautious outlook, leading to a neutral sentiment.
Key Financial Performance
Operating Expenses $18.7 million in 2024, a decrease of 17% from $22.6 million in 2023, which follows a 43% decrease from $40 million in 2022.
Adjusted EBITDA (Q4) $0.5 million in Q4 2024, an improvement of almost $5 million from a loss of $4.3 million in Q4 2023.
Adjusted EBITDA (Full Year) Loss of $1.1 million in 2024, an improvement of almost $7 million from an $8 million loss in 2023.
Revenue (Q4) $13.3 million in Q4 2024, a 25% increase from $10.7 million in Q4 2023, driven by a 280% increase in German revenue.
Revenue (Full Year) $54 million in 2024, an increase of $5.2 million or 11% from $48.8 million in 2023, attributed to accelerated growth in Germany.
Cost of Revenue (Q4) $10.7 million in Q4 2024, an increase of 12% from $9.6 million in Q4 2023, mainly due to increased material costs.
Gross Profit (Q4) $2.7 million in Q4 2024, an increase of 238% from $0.8 million in Q4 2023.
Gross Profit (Full Year) $8.5 million in 2024, a decrease of 14% from $9.8 million in 2023.
G&A Expenses (Full Year) $8 million in 2024, a decrease of 27% from $11 million in 2023.
G&A Expenses (Q4) $1.2 million in Q4 2024, a decrease of 64% from $3.3 million in Q4 2023.
Selling and Marketing Expenses (Full Year) $7.1 million in 2024, a decrease of 34% from $10.8 million in 2023.
Selling and Marketing Expenses (Q4) $1.8 million in Q4 2024, a decrease of 36% from $2.8 million in Q4 2023.
Net Loss (Full Year) $11.8 million in 2024, compared to $10.2 million in 2023.
Net Loss (Q4) $1.2 million in Q4 2024, compared to $3.5 million in Q4 2023.
Cash and Cash Equivalents $0.9 million as of December 31, 2024, down from $1.8 million on December 31, 2023.
Total Assets $39.2 million as of December 31, 2024, a decrease of 19.7% from $48.8 million on December 31, 2023.
Total Liabilities $36 million as of December 31, 2024, an increase of 3% from $35.1 million on December 31, 2023.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Strains Launched: Imported a total of 11 new strains in Germany in the second half of 2024 and launched 16 new strains in total for the year.
Strains Relaunched: Launched or relaunched 27 strains across six brands in Israel in 2024.
Revenue Growth in Germany: Sales in Germany increased by over 183% in 2024, contributing to 40% of total revenue in the second half of 2024.
Total Revenue: Total revenue for 2024 was $54 million, an increase of $5.2 million or 11% from 2023.
Operating Expenses Reduction: Reduced overall operating expenses by $4 million (17%) to $18.7 million in 2024, building on a 43% decrease in 2023.
Adjusted EBITDA Improvement: Adjusted EBITDA in Q4 2024 was a gain of $0.5 million, an improvement of almost $5 million from a loss of $4.3 million in Q4 2023.
Focus Shift to Germany: Strategically shifted focus towards the German market, consolidating resources and building a strong supply chain.
Cost Management Strategy: Implemented active cost management and full integration to drive efficiencies and support growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitive Pressures: The company emphasized the importance of maintaining a competitive edge in the dynamic cannabis market, indicating potential risks from competitors.
Regulatory Issues: The partial legalization of cannabis in Germany in April 2024 was highlighted as a significant change, suggesting that future regulatory developments could impact operations.
Supply Chain Challenges: The company noted that supply was a limiting factor for sales, particularly in Q4, indicating risks related to supply chain management.
Economic Factors: The decline in the number of medical cannabis patients in Israel due to the war was mentioned, which poses risks to revenue and market stability.
Inventory Management: The company faced challenges with slow-moving non-premium stock, leading to a significant write-off of $3.9 million, impacting gross margin and profit.
Financial Stability: The cancellation of the Oranim deal resulted in a revenue decrease of approximately $8.5 million, highlighting risks associated with business agreements and partnerships.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cost Management: Reduced overall operating expenses by $4 million (17%) to $18.7 million in 2024, building on a 43% decrease in 2023.
Supply Chain Integration: Fully integrated marketing and supply teams to build operational infrastructure and stable supply chain for growth in Germany.
New Product Launches: Imported 11 new strains in Germany in the second half of 2024, with an expected sales upside of 14%.
Sales Growth in Germany: Sales in Germany increased by over 183% in 2024, contributing to 40% of total revenue in the second half of 2024.
Operational Efficiency: Achieved a positive adjusted EBITDA of $0.5 million in Q4 2024, compared to a loss of $4.3 million in Q4 2023.
Revenue Expectations: Q1 2025 is expected to be the best quarter in sales to date in Germany.
Future Growth Strategy: Focus on external growth while maintaining efficiency and agility in the lean structure.
Cost of Sales: Do not anticipate a similar scale of inventory write-off in 2025 as experienced in 2024.
Financial Projections: Net loss for 2024 was $11.8 million, with a diluted loss per share of $4.51.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the dynamics in the German market that slowed growth in Q4?
A:In Q4, we had some delays, but Q1 looks very good. It's part of building the supply chain, which is a long process. We aim for a stable supply in '25.
Q:What changes are you seeing in the competitive dynamic for Germany?
A:The German market is very dynamic and competitive. We see the same leading competitors, and there is price compression, which is part of our plans.
Q:How should we think about the margin progression for the year with pricing pressure?
A:It's difficult to predict market development due to political changes, but we don't expect margins to decrease. We believe they might improve.
Q:Are you comfortable with the Israeli market now?
A:We don't foresee significant growth in the Israeli market; it will be stable unless regulations change. Our focus is mainly on Germany.
Q:Review of Unclear Management Responses
A:Management's response regarding the margin progression lacked clarity, particularly when discussing the impact of political changes in Germany and the specific expectations for future margins. Additionally, the response about the Israeli market's growth potential was vague, with no specific indicators of what regulatory changes could lead to growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Cannabis
Germany increase
Israel deal
Israel month
Israel net
Officer Birenberg
addition revocation
agreement cancellation
agreement effect
amount month
cancellation decrease
deal cancellation
decrease Israel
decrease increase
distribution
efficiency agility
efficiency ratio
expense outcome
improvement loss
increase Israel
increase material
integration
loss improvement
loss share
marketing
month st
net decrease
network
outcome deal
production
share period
st decrease
st increase
upside
IMCC Transcript
IM Cannabis Corp. (IMCC) Q1 2025 Earnings Call Transcript
Neutral5-15
IM Cannabis Corp. (IMCC) Q4 2024 Earnings Call Transcript
Unknown3-31
The earnings call reflects mixed signals: improved EBITDA and revenue growth in Germany, but significant net loss and inventory challenges. Regulatory changes in Germany and competitive pressures add uncertainty. The Q&A highlighted management's unclear responses, especially regarding margins. Despite some positive financial trends, the lack of a share repurchase program and cash position concerns suggest a cautious outlook, leading to a neutral sentiment.
IM Cannabis Corp. (IMCC) Q4 2024 Earnings Call Transcript
Unknown3-31
The earnings call summary presents a mixed picture. Positive aspects include a 53% reduction in operating expenses, positive adjusted EBITDA in Q4, and strong revenue growth in Germany. However, challenges like competitive pressures, supply chain issues, and a significant inventory write-off pose risks. The Q&A section reveals concerns about market dynamics and margin progression, with unclear guidance. Financial health is stable but not robust. Overall, the sentiment is neutral, with no strong catalysts for significant stock price movement.
IM Cannabis Corp. (IMCC) Q3 2024 Earnings Call Transcript
Unknown11-14
The earnings call presents mixed signals. Positive factors include strong growth in the German market, improved operational efficiency, and reduced losses. However, risks like supply chain challenges, regulatory issues, and competitive pressures counterbalance these positives. No guidance was provided, and there is no share buyback program to boost investor confidence. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction.
IMCC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
